{"id":403460,"date":"2020-12-21T07:05:34","date_gmt":"2020-12-21T12:05:34","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=403460"},"modified":"2020-12-21T07:05:34","modified_gmt":"2020-12-21T12:05:34","slug":"marinus-pharmaceuticals-announces-its-addition-to-the-nasdaq-biotechnology-index","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/marinus-pharmaceuticals-announces-its-addition-to-the-nasdaq-biotechnology-index\/","title":{"rendered":"Marinus Pharmaceuticals Announces Its Addition to the Nasdaq Biotechnology Index"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>Marinus Pharmaceuticals Announces Its Addition to the Nasdaq Biotechnology Index <\/b><\/p>\n<p>RADNOR, Pa.&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fmarinuspharma.com%2F&amp;esheet=52351507&amp;newsitemid=20201221005071&amp;lan=en-US&amp;anchor=Marinus+Pharmaceuticals%2C+Inc.&amp;index=1&amp;md5=73bde33add4dcbb3c886487460e5b9a5\">Marinus Pharmaceuticals, Inc.<\/a> (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced it has been selected for inclusion in the Nasdaq Biotechnology Index (NBI), which became effective prior to market open today.\n<\/p>\n<p>\n\u201cOn the tails of a momentous year, we are pleased to be included in the Nasdaq Biotechnology Index,\u201d said Scott Braunstein, M.D., Chief Executive Officer of Marinus Pharmaceuticals. \u201cIndex inclusion recognizes our clinical progress and heightened investor awareness as we remain committed to rapidly advancing our pipeline in rare epilepsies and neuropsychiatric disorders.\u201d\n<\/p>\n<p>\nThe NBI is designed to track the performance of a set of securities listed on The Nasdaq Stock Market that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark (ICB).\n<\/p>\n<p><b>About Marinus Pharmaceuticals<\/b><\/p>\n<p>\nMarinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders. Ganaxolone is a positive allosteric modulator of GABA<sub>A<\/sub> receptors that acts on a well-characterized target in the brain known to have anti-seizure, anti-depressant and anti-anxiety effects. Ganaxolone is being developed in IV and oral dose formulations intended to maximize therapeutic reach to adult and pediatric patient populations in both acute and chronic care settings. Marinus recently completed the first ever Phase 3 pivotal trial in children with CDKL5 deficiency disorder and is conducting a Phase 2 trial in tuberous sclerosis complex, as well as a Phase 2 biomarker-driven proof-of-concept trial in PCDH19-related epilepsy. The company has also initiated a Phase 3 trial in status epilepticus. For more information visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.marinuspharma.com&amp;esheet=52351507&amp;newsitemid=20201221005071&amp;lan=en-US&amp;anchor=www.marinuspharma.com&amp;index=2&amp;md5=ca3cf318cf6036e1f0cd5aa58ed4512a\">www.marinuspharma.com<\/a>.\n<\/p>\n<p><b>Forward-Looking Statements<\/b><\/p>\n<p>\nTo the extent that statements contained in this press release are not descriptions of historical facts regarding Marinus, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as \u201cmay\u201d, \u201cwill\u201d, \u201cexpect\u201d, \u201canticipate\u201d, \u201cestimate\u201d, \u201cintend\u201d, \u201cbelieve\u201d, and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Examples of forward-looking statements contained in this press release include, among others, statements regarding our clinical development plans for ganaxolone. Forward-looking statements in this release involve substantial risks and uncertainties that could cause our clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, uncertainties and delays relating to the design, enrollment, completion, and results of clinical trials; unanticipated costs and expenses; clinical trial results may not support further development in a specified indication or at all; actions or advice of the U.S. Food and Drug Administration may affect the design, initiation, timing, continuation and\/or progress of clinical trials or result in the need for additional clinical trials; our ability to obtain and maintain regulatory approval for our product candidate; delays, interruptions or failures in the manufacture and supply of our product candidate; our ability to raise additional capital; the effect of the COVID-19 pandemic on our business, the medical community and the global economy; and the availability or potential availability of alternative products or treatments for conditions targeted by us that could affect the availability or commercial potential of our product candidate. Marinus undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the Company in general, see filings Marinus has made with the Securities and Exchange Commission.\n<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201221005071r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20201221005071\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20201221005071\/en\/<\/a><\/span><\/p>\n<p>\nSasha Damouni Ellis<br \/>\n<br \/>Vice President, Investor Relations &amp; Corporate Communications<br \/>\n<br \/>Marinus Pharmaceuticals, Inc.<br \/>\n<br \/>484-253-6792<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:sdamouni@marinuspharma.com\">sdamouni@marinuspharma.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> Pennsylvania United States North America<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Biotechnology Health Science Pharmaceutical Research<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20201221005071\/en\/809242\/3\/marinus-logo-2in.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Marinus Pharmaceuticals Announces Its Addition to the Nasdaq Biotechnology Index RADNOR, Pa.&#8211;(BUSINESS WIRE)&#8211;Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced it has been selected for inclusion in the Nasdaq Biotechnology Index (NBI), which became effective prior to market open today. \u201cOn the tails of a momentous year, we are pleased to be included in the Nasdaq Biotechnology Index,\u201d said Scott Braunstein, M.D., Chief Executive Officer of Marinus Pharmaceuticals. \u201cIndex inclusion recognizes our clinical progress and heightened investor awareness as we remain committed to rapidly advancing our pipeline in rare epilepsies and neuropsychiatric disorders.\u201d The NBI is designed to track the performance of a set of securities &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/marinus-pharmaceuticals-announces-its-addition-to-the-nasdaq-biotechnology-index\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Marinus Pharmaceuticals Announces Its Addition to the Nasdaq Biotechnology Index&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-403460","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Marinus Pharmaceuticals Announces Its Addition to the Nasdaq Biotechnology Index - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/marinus-pharmaceuticals-announces-its-addition-to-the-nasdaq-biotechnology-index\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Marinus Pharmaceuticals Announces Its Addition to the Nasdaq Biotechnology Index - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Marinus Pharmaceuticals Announces Its Addition to the Nasdaq Biotechnology Index RADNOR, Pa.&#8211;(BUSINESS WIRE)&#8211;Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced it has been selected for inclusion in the Nasdaq Biotechnology Index (NBI), which became effective prior to market open today. \u201cOn the tails of a momentous year, we are pleased to be included in the Nasdaq Biotechnology Index,\u201d said Scott Braunstein, M.D., Chief Executive Officer of Marinus Pharmaceuticals. \u201cIndex inclusion recognizes our clinical progress and heightened investor awareness as we remain committed to rapidly advancing our pipeline in rare epilepsies and neuropsychiatric disorders.\u201d The NBI is designed to track the performance of a set of securities &hellip; Continue reading &quot;Marinus Pharmaceuticals Announces Its Addition to the Nasdaq Biotechnology Index&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/marinus-pharmaceuticals-announces-its-addition-to-the-nasdaq-biotechnology-index\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-12-21T12:05:34+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201221005071r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/marinus-pharmaceuticals-announces-its-addition-to-the-nasdaq-biotechnology-index\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/marinus-pharmaceuticals-announces-its-addition-to-the-nasdaq-biotechnology-index\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Marinus Pharmaceuticals Announces Its Addition to the Nasdaq Biotechnology Index\",\"datePublished\":\"2020-12-21T12:05:34+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/marinus-pharmaceuticals-announces-its-addition-to-the-nasdaq-biotechnology-index\\\/\"},\"wordCount\":671,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/marinus-pharmaceuticals-announces-its-addition-to-the-nasdaq-biotechnology-index\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20201221005071r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/marinus-pharmaceuticals-announces-its-addition-to-the-nasdaq-biotechnology-index\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/marinus-pharmaceuticals-announces-its-addition-to-the-nasdaq-biotechnology-index\\\/\",\"name\":\"Marinus Pharmaceuticals Announces Its Addition to the Nasdaq Biotechnology Index - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/marinus-pharmaceuticals-announces-its-addition-to-the-nasdaq-biotechnology-index\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/marinus-pharmaceuticals-announces-its-addition-to-the-nasdaq-biotechnology-index\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20201221005071r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2020-12-21T12:05:34+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/marinus-pharmaceuticals-announces-its-addition-to-the-nasdaq-biotechnology-index\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/marinus-pharmaceuticals-announces-its-addition-to-the-nasdaq-biotechnology-index\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/marinus-pharmaceuticals-announces-its-addition-to-the-nasdaq-biotechnology-index\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20201221005071r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20201221005071r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/marinus-pharmaceuticals-announces-its-addition-to-the-nasdaq-biotechnology-index\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Marinus Pharmaceuticals Announces Its Addition to the Nasdaq Biotechnology Index\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Marinus Pharmaceuticals Announces Its Addition to the Nasdaq Biotechnology Index - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/marinus-pharmaceuticals-announces-its-addition-to-the-nasdaq-biotechnology-index\/","og_locale":"en_US","og_type":"article","og_title":"Marinus Pharmaceuticals Announces Its Addition to the Nasdaq Biotechnology Index - Market Newsdesk","og_description":"Marinus Pharmaceuticals Announces Its Addition to the Nasdaq Biotechnology Index RADNOR, Pa.&#8211;(BUSINESS WIRE)&#8211;Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced it has been selected for inclusion in the Nasdaq Biotechnology Index (NBI), which became effective prior to market open today. \u201cOn the tails of a momentous year, we are pleased to be included in the Nasdaq Biotechnology Index,\u201d said Scott Braunstein, M.D., Chief Executive Officer of Marinus Pharmaceuticals. \u201cIndex inclusion recognizes our clinical progress and heightened investor awareness as we remain committed to rapidly advancing our pipeline in rare epilepsies and neuropsychiatric disorders.\u201d The NBI is designed to track the performance of a set of securities &hellip; Continue reading \"Marinus Pharmaceuticals Announces Its Addition to the Nasdaq Biotechnology Index\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/marinus-pharmaceuticals-announces-its-addition-to-the-nasdaq-biotechnology-index\/","og_site_name":"Market Newsdesk","article_published_time":"2020-12-21T12:05:34+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201221005071r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/marinus-pharmaceuticals-announces-its-addition-to-the-nasdaq-biotechnology-index\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/marinus-pharmaceuticals-announces-its-addition-to-the-nasdaq-biotechnology-index\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Marinus Pharmaceuticals Announces Its Addition to the Nasdaq Biotechnology Index","datePublished":"2020-12-21T12:05:34+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/marinus-pharmaceuticals-announces-its-addition-to-the-nasdaq-biotechnology-index\/"},"wordCount":671,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/marinus-pharmaceuticals-announces-its-addition-to-the-nasdaq-biotechnology-index\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201221005071r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/marinus-pharmaceuticals-announces-its-addition-to-the-nasdaq-biotechnology-index\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/marinus-pharmaceuticals-announces-its-addition-to-the-nasdaq-biotechnology-index\/","name":"Marinus Pharmaceuticals Announces Its Addition to the Nasdaq Biotechnology Index - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/marinus-pharmaceuticals-announces-its-addition-to-the-nasdaq-biotechnology-index\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/marinus-pharmaceuticals-announces-its-addition-to-the-nasdaq-biotechnology-index\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201221005071r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2020-12-21T12:05:34+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/marinus-pharmaceuticals-announces-its-addition-to-the-nasdaq-biotechnology-index\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/marinus-pharmaceuticals-announces-its-addition-to-the-nasdaq-biotechnology-index\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/marinus-pharmaceuticals-announces-its-addition-to-the-nasdaq-biotechnology-index\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201221005071r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201221005071r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/marinus-pharmaceuticals-announces-its-addition-to-the-nasdaq-biotechnology-index\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Marinus Pharmaceuticals Announces Its Addition to the Nasdaq Biotechnology Index"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/403460","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=403460"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/403460\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=403460"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=403460"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=403460"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}